173 related articles for article (PubMed ID: 21610081)
1. A survey of antiprion compounds reveals the prevalence of non-PrP molecular targets.
Poncet-Montange G; St Martin SJ; Bogatova OV; Prusiner SB; Shoichet BK; Ghaemmaghami S
J Biol Chem; 2011 Aug; 286(31):27718-28. PubMed ID: 21610081
[TBL] [Abstract][Full Text] [Related]
2. Antiprion Activity of DB772 and Related Monothiophene- and Furan-Based Analogs in a Persistently Infected Ovine Microglia Culture System.
Dinkel KD; Stanton JB; Boykin DW; Stephens CE; Madsen-Bouterse SA; Schneider DA
Antimicrob Agents Chemother; 2016 Sep; 60(9):5467-82. PubMed ID: 27381401
[TBL] [Abstract][Full Text] [Related]
3. Discovery of 2-aminothiazoles as potent antiprion compounds.
Ghaemmaghami S; May BC; Renslo AR; Prusiner SB
J Virol; 2010 Apr; 84(7):3408-12. PubMed ID: 20032192
[TBL] [Abstract][Full Text] [Related]
4. Polythiophenes inhibit prion propagation by stabilizing prion protein (PrP) aggregates.
Margalith I; Suter C; Ballmer B; Schwarz P; Tiberi C; Sonati T; Falsig J; Nyström S; Hammarström P; Aslund A; Nilsson KP; Yam A; Whitters E; Hornemann S; Aguzzi A
J Biol Chem; 2012 Jun; 287(23):18872-87. PubMed ID: 22493452
[TBL] [Abstract][Full Text] [Related]
5. Influence of surface groups on poly(propylene imine) dendrimers antiprion activity.
McCarthy JM; Rasines Moreno B; Filippini D; Komber H; Maly M; Cernescu M; Brutschy B; Appelhans D; Rogers MS
Biomacromolecules; 2013 Jan; 14(1):27-37. PubMed ID: 23234313
[TBL] [Abstract][Full Text] [Related]
6. A Promising Antiprion Trimethoxychalcone Binds to the Globular Domain of the Cellular Prion Protein and Changes Its Cellular Location.
Ferreira NC; Ascari LM; Hughson AG; Cavalheiro GR; Góes CF; Fernandes PN; Hollister JR; da Conceição RA; Silva DS; Souza AMT; Barbosa MLC; Lara FA; Martins RAP; Caughey B; Cordeiro Y
Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29133563
[TBL] [Abstract][Full Text] [Related]
7. Molecular Dynamics Simulation Study on the Binding and Stabilization Mechanism of Antiprion Compounds to the "Hot Spot" Region of PrP
Zhou S; Liu X; An X; Yao X; Liu H
ACS Chem Neurosci; 2017 Nov; 8(11):2446-2456. PubMed ID: 28795797
[TBL] [Abstract][Full Text] [Related]
8. Differential inhibition of prion propagation by enantiomers of quinacrine.
Ryou C; Legname G; Peretz D; Craig JC; Baldwin MA; Prusiner SB
Lab Invest; 2003 Jun; 83(6):837-43. PubMed ID: 12808118
[TBL] [Abstract][Full Text] [Related]
9. Anti-prion drug mPPIg5 inhibits PrP(C) conversion to PrP(Sc).
McCarthy JM; Franke M; Resenberger UK; Waldron S; Simpson JC; Tatzelt J; Appelhans D; Rogers MS
PLoS One; 2013; 8(1):e55282. PubMed ID: 23383136
[TBL] [Abstract][Full Text] [Related]
10. Identification of Anti-prion Compounds using a Novel Cellular Assay.
Imberdis T; Heeres JT; Yueh H; Fang C; Zhen J; Rich CB; Glicksman M; Beeler AB; Harris DA
J Biol Chem; 2016 Dec; 291(50):26164-26176. PubMed ID: 27803163
[TBL] [Abstract][Full Text] [Related]
11. Antiprion compounds that reduce PrP(Sc) levels in dividing and stationary-phase cells.
Silber BM; Gever JR; Li Z; Gallardo-Godoy A; Renslo AR; Widjaja K; Irwin JJ; Rao S; Jacobson MP; Ghaemmaghami S; Prusiner SB
Bioorg Med Chem; 2013 Dec; 21(24):7999-8012. PubMed ID: 24183589
[TBL] [Abstract][Full Text] [Related]
12. Antiprion properties of prion protein-derived cell-penetrating peptides.
Löfgren K; Wahlström A; Lundberg P; Langel U; Gräslund A; Bedecs K
FASEB J; 2008 Jul; 22(7):2177-84. PubMed ID: 18296502
[TBL] [Abstract][Full Text] [Related]
13. Charged bipolar suramin derivatives induce aggregation of the prion protein at the cell surface and inhibit PrPSc replication.
Nunziante M; Kehler C; Maas E; Kassack MU; Groschup M; Schätzl HM
J Cell Sci; 2005 Nov; 118(Pt 21):4959-73. PubMed ID: 16219680
[TBL] [Abstract][Full Text] [Related]
14. Effects of new amphotericin analogues on the scrapie isoform of the prion protein.
Soler L; Caffrey P; McMahon HE
Biochim Biophys Acta; 2008 Oct; 1780(10):1162-7. PubMed ID: 18691635
[TBL] [Abstract][Full Text] [Related]
15. Influence of surface functionality of poly(propylene imine) dendrimers on protease resistance and propagation of the scrapie prion protein.
Fischer M; Appelhans D; Schwarz S; Klajnert B; Bryszewska M; Voit B; Rogers M
Biomacromolecules; 2010 May; 11(5):1314-25. PubMed ID: 20405854
[TBL] [Abstract][Full Text] [Related]
16. Procedure for identification and characterization of drugs efficient against mammalian prion: from a yeast-based antiprion drug screening assay to in vivo mouse models.
Voisset C; Saupe SJ; Galons H; Blondel M
Infect Disord Drug Targets; 2009 Feb; 9(1):31-9. PubMed ID: 19200013
[TBL] [Abstract][Full Text] [Related]
17. Combining autophagy stimulators and cellulose ethers for therapy against prion disease.
Abdulrahman BA; Tahir W; Doh-Ura K; Gilch S; Schatzl HM
Prion; 2019 Jan; 13(1):185-196. PubMed ID: 31578923
[TBL] [Abstract][Full Text] [Related]
18. In silico studies and fluorescence binding assays of potential anti-prion compounds reveal an important binding site for prion inhibition from PrP(C) to PrP(Sc).
Pagadala NS; Perez-Pineiro R; Wishart DS; Tuszynski JA
Eur J Med Chem; 2015 Feb; 91():118-31. PubMed ID: 25042003
[TBL] [Abstract][Full Text] [Related]
19. Complementarity determining regions of an anti-prion protein scFv fragment orchestrate conformation specificity and antiprion activity.
Müller-Schiffmann A; Petsch B; Leliveld SR; Muyrers J; Salwierz A; Mangels C; Schwarzinger S; Riesner D; Stitz L; Korth C
Mol Immunol; 2009 Feb; 46(4):532-40. PubMed ID: 18973947
[TBL] [Abstract][Full Text] [Related]
20. Lactoferrin induces cell surface retention of prion protein and inhibits prion accumulation.
Iwamaru Y; Shimizu Y; Imamura M; Murayama Y; Endo R; Tagawa Y; Ushiki-Kaku Y; Takenouchi T; Kitani H; Mohri S; Yokoyama T; Okada H
J Neurochem; 2008 Nov; 107(3):636-46. PubMed ID: 18717818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
